Search the Newsreel

Teva Pharmaceutical Industries (TEVA) Stock Analysis: Exploring a 16.52% Upside Potential

Teva Pharmaceutical Industries (TEVA) shows a potential upside of 16.52% according to analysts, with an average price target of $41.20. Despite a slight revenue decline, the company boasts strong operational efficiency and a diverse product portfolio in generic and specialty medicines. While it doesn't …

How Corteva Inc. (CTVA) Affects Rotational Strategy Timing

Corteva Inc. (CTVA) is showing weak near and mid-term sentiment, posing a challenge to its long-term positive outlook. The analysis highlights an elevated downside risk with no additional long-term support signals remaining. Institutional trading strategies, including position, momentum breakout, and risk hedging, have been …

Pharma Giant Teva Seeks to Hide Israel Ties From Jury in Price-fixing Trial

Teva Pharmaceuticals has requested that a U.S. judge prevent insurer Humana from revealing its Israeli origins to jurors in an upcoming price-fixing trial. The company argues that strong public sentiment regarding the Gaza war could prejudice the proceedings and hinder its ability to receive …

How Q2 Results and Alina GLP-1 Approvals At Stevanato Group (STVN) Have Changed Its Investment Story

Stevanato Group (STVN) recently reported mixed Q2 2026 results with increased sales but decreased net income and slightly narrowed full-year guidance. Simultaneously, European marketing authorizations for its Alina GLP-1 variable-dose pen injector platform highlight the company's growing presence in self-administered injectable therapies, offering tangible …

Empowered Funds LLC Increases Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Projeções de Resultados: Corteva Inc (CTVA) — LPA e Crescimento de Receita

Teva Pharmaceutical Industries (TEVA) Lifts Outlook On Earnings As Valuation Debate Stays Open

Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History

This Yahoo Finance page provides comprehensive information on Teva Pharmaceutical Industries Limited (TEVA), including its current stock price, news headlines, and historical performance data. The stock closed at $35.36, up 1.58% on August 7, and traded slightly down in after-hours. The news section highlights …

PensionDanmark Pensionsforsikringsaktieselskab Sells 35,576 Shares of Corteva, Inc. $CTVA

PensionDanmark Pensionsforsikringsaktieselskab significantly reduced its stake in Corteva, Inc. by selling 35,576 shares, bringing its total holdings to 146,962 shares valued at approximately $12.45 million. Despite this sale, institutional investors collectively own 81.54% of Corteva. The company reported strong quarterly EPS, beating estimates, and …

Assenagon Asset Management S.A. Grows Position in Teva Pharmaceutical Industries Ltd. $TEVA

Assenagon Asset Management S.A. significantly increased its stake in Teva Pharmaceutical Industries Ltd. by 128.1% in the second quarter, now holding over 3 million shares valued at approximately $103.5 million. Institutional investors collectively own 54.05% of Teva, and analysts maintain a "Moderate Buy" rating …

Enterprise value to EBITDA forward of Corteva Inc – MUN:2X0

This page provides financial information for Corteva Inc (MUN:2X0), specifically focusing on its enterprise value to EBITDA forward. It indicates that the market for this stock is currently closed with no trades. The content is primarily a financial data point with surrounding navigation and …

Projeções de Resultados: Teva Pharmaceutical Industries Ltd (TEVA) — LPA e Crescimento de Receita

Stevanato Group S.p.A. SEC Filing (Aug 7, 2026)

Stevanato Group S.p.A. (STVN) filed a Form 144 with the SEC on August 7, 2026, indicating a proposed sale of 4,209 ordinary shares by Citigroup Global Markets, Inc. The shares were acquired on August 6, 2026, through restricted stock vesting as payment for services …

Liraglutide combination products using Stevanato Group pen gain European approval

Stevanato Group's liraglutide-based combination products, utilizing their Alina pen injector platform, have received marketing authorizations in Europe. The approvals are for Alina 30, designed for diabetes therapies, and Alina 50, intended for weight management applications, both part of a broader variable-dose platform for injectable …

Corteva Inc (CTVA) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Corteva Inc (CTVA), noting its current earnings forecast score of 7.74, ranking 24th in the Chemicals industry. Analysts have set an average price target of $78.00, with a majority recommending a "Buy" rating. The company's expected revenue …

Form 8K Corteva Inc For: 6 August By Investing.com

This article announces the filing of a Form 8K by Corteva Inc. on August 6th. The content is brief and primarily serves as a notification of this corporate filing, with no additional details provided within the article itself. It includes various financial market data …

Arrowstreet Capital Limited Partnership Reduces Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Arrowstreet Capital Limited Partnership significantly reduced its stake in Teva Pharmaceutical Industries Ltd. by 72.9% in the first quarter, selling 104,530 shares and retaining 38,900 shares worth $1.17 million. Despite this reduction and an insider sale, institutional investors still hold a majority stake of …

Why Corteva (CTVA) Raised EPS Guidance After Weaker Q2 Results And What That Really Signals

Corteva (CTVA) recently reported weaker Q2 2026 results with declining sales and net income but raised its full-year operating EPS guidance to US$3.60–US$3.80, signaling management's confidence in strong execution. This move, despite ongoing pricing pressure and competition in Crop Protection, repositions Corteva’s investment narrative, …

Corteva Inc. stock underperforms Thursday when compared to competitors

Corteva Inc. shares fell 2.30% on Thursday, closing at $76.86, despite a two-day winning streak being broken. This underperformance occurred on a tough trading day where the S&P 500 Index also declined by 0.18% and the Dow Jones Industrial Average fell by 0.85%. The …

Corteva Announces Private Exchange Offers and Consent Solicitations for EIDP's 2.300% Senior Notes Due 2030, 5.125% Senior Notes Due 2032 and 4.800% Senior Notes Due 2033

INDIANAPOLIS, Aug. 6, 2026 /PRNewswire/ -- Corteva, Inc. (NYSE: CTVA) announced today that Vylor Inc., a Delaware corporation and its wholly owned subsidiary ("Vylor"), has commenced private offers to exchange (with respect to each series, an "Exchange Offer" and together, the "Exchange Offers") any …

Eligible noteholders may exchange EIDP debt for equal Vylor notes by Aug. 19

Corteva (NYSE: CTVA) has initiated private exchange offers for outstanding senior notes of its subsidiary EIDP, totaling $1.6 billion, in preparation for the separation of its seed business into a new entity, Vylor. Eligible noteholders who tender their EIDP notes by August 19, 2026, …

Stevanato Group (NYSE: STVN) targets 26.8% 2026 EBITDA margin

Stevanato Group reported strong Q2 2026 results with an 8% revenue increase and a 26% adjusted EBITDA margin, driven by growth in its Biopharmaceutical and Diagnostic Solutions (BDS) segment and High Value Solutions. The company updated its full-year 2026 guidance, targeting a 26.8% adjusted …

Citing Gaza war, pharma giant Teva doesn't want US jurors in price-fixing trial to know it's Israeli

Teva Pharmaceuticals has requested a US judge to prevent insurer Humana from revealing its Israeli nationality to jurors in an upcoming price-fixing trial. The company argues that strong public sentiment regarding the Gaza war could prejudice the proceedings and hinder its ability to receive …

Teva seeks to keep Israel ties from jury, cites Gaza war

Teva Pharmaceuticals has asked a U.S. judge to prevent insurer Humana from informing jurors that Teva is an Israeli company during an upcoming drug price-fixing trial. Teva argues that strong public sentiment surrounding the Gaza war could prejudice the proceedings and hinder its ability …

Teva Pharmaceutical Industries Ltd (TEVA) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Teva Pharmaceutical (TEVA) R&D chief exercises RSUs, sells shares

Teva Pharmaceutical Industries' Executive Vice President, Global R&D and Chief Medical Officer, Eric A. Hughes, exercised 52,744 restricted share units (RSUs) on August 3, 2026. Subsequently, he sold 25,578 ordinary shares at a weighted average price of $34.8757 per share to cover tax withholding …

Teva Pharmaceutical Industries (TEVA) exec sells 12,827 shares under 10b5-1 plan

Teva Pharmaceutical Industries executive Placid Jover sold 12,827 ordinary shares for approximately $447,000 on August 3, 2026, after converting restricted share units. The sale was executed under a Rule 10b5-1 trading plan to cover tax withholding obligations. Following the transaction, Jover retains 25,657 restricted …

Stevanato Group S.p.A. Stock 12‑Month Price Target Raised to $25.1, Implies 28% Upside

Stevanato Group S.p.A.'s average stock price target has been raised from $24.95 to $25.1 by 10 analysts, suggesting a potential 28% upside from the August 4th closing price. The consensus rating among 12 covering analysts remains a "Buy," with 10 Buys and 2 Holds. …

Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task. That's …

Stevanato Group Details Mid-2026 Performance and Risk Landscape in Unaudited Interim Report

Stevanato Group has filed an unaudited interim report for Q2 2026, outlining its financial performance and discussing key operational risks such as supply chain issues, geopolitical tensions, and post-pandemic demand normalization. The report emphasizes the importance of quality, innovation, and brand reputation for competitiveness. …

Earnings call transcript: Royalty Pharma lifts 2026 outlook in strong Q2

335,493 Shares in Stevanato Group S.p.A. $STVN Purchased by Confluence Investment Management LLC

Confluence Investment Management LLC has purchased a new stake of 335,493 shares in Stevanato Group S.p.A., valued at approximately $6.06 million, representing 0.11% of the company. Other institutional investors like Conestoga Capital Advisors, Van Berkom & Associates, Jennison Associates, and Roubaix Capital also increased …

Cooper Investors PTY Ltd. Makes New $2.69 Million Investment in Corteva, Inc. $CTVA

Cooper Investors PTY Ltd. has made a new investment of

Stevanato Group SpA (STVN) (Q2 2026) Earnings Call Highlights: Biologics Surge and Alina ...

Stevanato Group (STVN) reported an 8% revenue increase in Q2 2026, driven by a 9% rise in biopharmaceutical and diagnostic solutions and a 30% surge in biologics revenue. The company saw an adjusted EBITDA margin expansion to 26% and achieved a significant milestone with …

Stevanato Group (STVN) Stock Faces Cash Strain Despite Margin Gains

Stevanato (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group (STVN) reported an 8% revenue increase in Q2 2026, driven by a 9% rise in biopharmaceutical and diagnostic solutions and a 30% surge in biologics revenue. The company saw an adjusted EBITDA margin expansion to 26% and achieved a significant milestone with …